Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III double-blind placebo-controlled durability trial of recombinant zoster vaccine (CHO cell) in adults aged 40 years and older
CTR20261373Phase 3Active
- Sponsor
- Recbio
- Start
- Apr 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in herpes zoster (HZ) comparing Recombinant Zoster Vaccine (CHO Cell) with Placebo (2 arms). Primary endpoint: Person-year incidence of confirmed herpes zoster cases in adults aged 40 years and older from 13 to 36 months after full vaccination. Started Apr 2026; status: active.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on CTR20261373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261373.